Skip to main content

A Fluorescence-Based Screening Assay for Identification of Hepatitis C Virus NS3 Helicase Inhibitors and Characterization of Their Inhibitory Mechanism

  • Protocol
  • First Online:
RNA Remodeling Proteins

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1259))

Abstract

Hepatitis C virus (HCV) can establish a chronic infection in the majority of individuals infected, resulting in liver cirrhosis and hepatocellular carcinoma. Because the current standard treatment for HCV infection has limitations in terms of severe side effects, the emergence of drug resistance, and drug–drug interactions, it is desirable to develop novel antivirals that target viral proteins involved in viral replication. HCV nonstructural protein 3 (NS3) helicase, which unwinds double-stranded nucleic acids to yield single-stranded nucleic acids, is one possible target for new drug development, because it plays an essential role in viral replication. In this chapter, we describe a helicase assay based on fluorescence resonance energy transfer (FRET) that can be used for high-throughput screening of HCV NS3 helicase inhibitors. The assay uses a double-stranded RNA (dsRNA) substrate with a fluorophore-labeled strand hybridized to a quencher-labeled strand and monitors the increase in fluorescence intensity resulting from helicase-catalyzed unwinding of the dsRNA substrate. We further describe radioactive assays to directly visualize RNA strands unwound by helicase and to evaluate the ATPase and RNA-binding activities of NS3, which are linked to helicase activity, for characterization of the inhibitory mechanism.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ghany MG, Nelson DR, Strader DB et al (2011) An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 54:1433–1444

    Article  PubMed Central  PubMed  Google Scholar 

  2. Liang TJ, Ghany MG (2013) Current and future therapies for hepatitis C virus infection. N Engl J Med 368:1907–1917

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  3. Sarrazin C, Hézode C, Zeuzem S et al (2012) Antiviral strategies in hepatitis C virus infection. J Hepatol 56(Suppl 1):S88–S100

    Article  CAS  PubMed  Google Scholar 

  4. Scheel TKH, Rice CM (2013) Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med 19:837–849

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Gallinari P, Brennan D, Nardi C et al (1998) Multiple enzymatic activities associated with recombinant NS3 protein of hepatitis C virus. J Virol 72:6758–6769

    CAS  PubMed Central  PubMed  Google Scholar 

  6. Lam AMI, Frick DN (2006) Hepatitis C virus subgenomic replicon requires an active NS3 RNA helicase. J Virol 80:404–411

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Kwong AD, Rao BG, Jeang K-T (2005) Viral and cellular RNA helicases as antiviral targets. Nat Rev Drug Discov 4:845–853

    Article  CAS  PubMed  Google Scholar 

  8. Kim DW, Gwack Y, Han JH et al (1995) C-terminal domain of the hepatitis C virus NS3 protein contains an RNA helicase activity. Biochem Biophys Res Commun 215:160–166

    Article  CAS  PubMed  Google Scholar 

  9. Tai CL, Chi WK, Chen DS et al (1996) The helicase activity associated with hepatitis C virus nonstructural protein 3 (NS3). J Virol 70:8477–8484

    CAS  PubMed Central  PubMed  Google Scholar 

  10. Gwack Y, Kim DW, Han JH et al (1996) Characterization of RNA binding activity and RNA helicase activity of the hepatitis C virus NS3 protein. Biochem Biophys Res Commun 225:654–659

    Article  CAS  PubMed  Google Scholar 

  11. Gwack Y, Kim DW, Han JH et al (1997) DNA helicase activity of the hepatitis C virus nonstructural protein 3. Eur J Biochem 250:47–54

    Article  CAS  PubMed  Google Scholar 

  12. Matson SW, Kaiser-Rogers KA (1990) DNA helicases. Annu Rev Biochem 59:289–329

    Article  CAS  PubMed  Google Scholar 

  13. Zhang C, Cai Z, Kim Y-C et al (2005) Stimulation of hepatitis C virus (HCV) nonstructural protein 3 (NS3) helicase activity by the NS3 protease domain and by HCV RNA-dependent RNA polymerase. J Virol 79:8687–8697

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Bjornson KP, Amaratunga M, Moore KJM et al (1994) Single-turnover kinetics of helicase-catalyzed DNA unwinding monitored continuously by fluorescence energy transfer. Biochemistry 33:14306–14316

    Article  CAS  PubMed  Google Scholar 

  15. Boguszewska-Chachulska AM, Krawczyk M, Stankiewicz A et al (2004) Direct fluorometric measurement of hepatitis C virus helicase activity. FEBS Lett 567:253–258

    Article  CAS  PubMed  Google Scholar 

  16. Belon CA, Frick DN (2008) Monitoring helicase activity with molecular beacons. Biotechniques 45:433–442

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Tani H, Fujita O, Furuta A et al (2010) Real-time monitoring of RNA helicase activity using fluorescence resonance energy transfer in vitro. Biochem Biophys Res Commun 393:131–136

    Article  CAS  PubMed  Google Scholar 

  18. Salam KA, Furuta A, Noda N et al (2012) Inhibition of hepatitis C virus NS3 helicase by manoalide. J Nat Prod 75:650–654

    Article  CAS  PubMed  Google Scholar 

  19. Furuta A, Salam KA, Akimitsu N et al (2014) Cholesterol sulfate as a potential inhibitor of hepatitis C virus NS3 helicase. J Enzyme Inhib Med Chem 29:223–229

    Article  CAS  PubMed  Google Scholar 

  20. Fujimoto Y, Salam KA, Furuta A et al (2012) Inhibition of both protease and helicase activities of hepatitis C virus NS3 by an ethyl acetate extract of marine sponge Amphimedon sp. PLoS One 7:e48685

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Yamashita A, Salam KA, Furuta A et al (2012) Inhibition of hepatitis C virus replication and viral helicase by ethyl acetate extract of the marine feather star Alloeocomatella polycladia. Mar Drugs 10:744–761

    Article  PubMed Central  PubMed  Google Scholar 

  22. Salam KA, Furuta A, Noda N et al (2013) Psammaplin A inhibits hepatitis C virus NS3 helicase. J Nat Med 67:765–772

    Article  CAS  PubMed  Google Scholar 

  23. Furuta A, Salam KA, Hermawan I et al (2014) Identification and biochemical characterization of halisulfate 3 and suvanine as novel inhibitors of hepatitis C virus NS3 helicase from a marine sponge. Mar Drugs 12:462–476

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  24. Belon CA, Frick DN (2009) Helicase inhibitors as specifically targeted antiviral therapy for hepatitis C. Future Virol 4:277–293

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  25. Tani H, Akimitsu N, Fujita O et al (2009) High-throughput screening assay of hepatitis C virus helicase inhibitors using fluorescence-quenching phenomenon. Biochem Biophys Res Commun 379:1054–1059

    Article  CAS  PubMed  Google Scholar 

  26. Nishikawa F, Funaji K, Fukuda K et al (2004) In vitro selection of RNA aptamers against the HCV NS3 helicase domain. Oligonucleotides 14:114–129

    Article  CAS  PubMed  Google Scholar 

  27. Copeland RA (2005) Evaluation of enzyme inhibitors in drug discovery. Wiley, New York

    Google Scholar 

Download references

Acknowledgements

The authors thank Dr. J. Tanaka (University of the Ryukyus) for his kind gift of the HCV NS3 inhibitors and Dr. S. Nishikawa (AIST) for providing the expression vector of full length HCV-NS3. The Global COE Program “Center for Practical Chemical Wisdom” of the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan partially supported this work.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Naohiro Noda .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this protocol

Cite this protocol

Furuta, A. et al. (2015). A Fluorescence-Based Screening Assay for Identification of Hepatitis C Virus NS3 Helicase Inhibitors and Characterization of Their Inhibitory Mechanism. In: Boudvillain, M. (eds) RNA Remodeling Proteins. Methods in Molecular Biology, vol 1259. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-2214-7_14

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-2214-7_14

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-2213-0

  • Online ISBN: 978-1-4939-2214-7

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics